Latest Conference Articles

February 29th 2020, 3:00am

HCC-TAG Conference

Ghassan K. Abou-Alfa, MD, discusses ways to optimize treatment selection for patients with hepatocellular carcinoma.

February 29th 2020, 2:21am

HCC-TAG Conference

Findings from the phase III IMbrave 150 trial represented the first time a treatment outperformed sorafenib for overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC), and the HCC world was understandably excited, said Ghassan K. Abou-Alfa, MD.

February 29th 2020, 12:27am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Newly approved and investigational agents are joining ruxolitinib for the treatment of myelofibrosis and may provide options for patients who progress or become intolerant to frontline JAK inhibitors.

February 28th 2020, 11:59pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Sagar Lonial, MD, FACP, discusses how the treatment landscape has evolved for patients with smoldering multiple myeloma.

February 28th 2020, 11:43pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jae H. Park, MD, discusses the challenges in using CAR T-cell therapy in adult patients with acute lymphoblastic leukemia, and also highlights the potential role for off-the-shelf CAR T cells.

February 28th 2020, 9:42pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Despite advances made in the treatment of patients with diffuse large B-cell lymphoma, investigators are on a quest to move more novel agents through the pipeline, says Craig Moskowitz, MD, in a presentation during the 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.

February 28th 2020, 11:06am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Prasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

February 28th 2020, 8:55am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Joshua Brody, MD, discusses the development of in situ vaccinations, a vaccine that is created at the tumor site in patients with cancer.

February 24th 2020, 6:06am

Transplantation and Cellular Therapy Meetings

Anthony D. Sung, MD, discusses the findings from the phase II trial of pasireotide as a method to prevent gastrointestinal toxicity and acute graft-versus-host-disease in patients who undergo allogeneic hematopoietic stem cell transplant.

February 23rd 2020, 2:28am

Transplantation and Cellular Therapy Meetings

David G. Maloney, MD, PhD, discusses the value of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive lymphomas.

February 23rd 2020, 2:20am

Transplantation and Cellular Therapy Meetings

Narsoplimab (OMS721) is advancing through the therapy pipeline as a novel treatment option for patients with transplant-associated thrombotic microangiopathy.

February 23rd 2020, 2:12am

Transplantation and Cellular Therapy Meetings

David Miklos, MD, discusses the results from the ZUMA-2 trial evaluating KTE-X19 in patients with relapsed/refractory mantle cell lymphoma.

February 23rd 2020, 2:00am

Transplantation and Cellular Therapy Meetings

Christopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.

February 22nd 2020, 2:14am

Transplantation and Cellular Therapy Meetings

An “off-the-shelf” Epstein Barr-virus–specific cytotoxic lymphocyte CAR product derived from cells harvested from third-party donors induced a 100% response rate in adult and pediatric patients with relapsed/refractory non-Hodgkin lymphoma.

February 22nd 2020, 12:58am

Transplantation and Cellular Therapy Meetings

Craig Sauter, MD, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor T-cell therapy.

February 22nd 2020, 12:45am

Transplantation and Cellular Therapy Meetings

Sergio A. Giralt, MD, discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy.

February 22nd 2020, 12:36am

Transplantation and Cellular Therapy Meetings

Early steroid intervention has the potential to reduce the severity of adverse events associated with axicabtagene ciloleucel in patients with refractory large B-cell lymphoma, according to an analysis of the phase I/II ZUMA-1 trial.

February 21st 2020, 9:38pm

Transplantation and Cellular Therapy Meetings

Iodine (131I) apamistamab (Iomab-B) conditioning induced a complete remission in 84% (31/38) of patients with active acute myeloid leukemia, who were then able to receive allogeneic hematopoietic stem cell transplant, according to preliminary results from the phase III SIERRA trial.

February 21st 2020, 9:19pm

Transplantation and Cellular Therapy Meetings

Carlos R. Bachier, MD, discusses the toxicity profile of lisocabtagene maraleucel that has been observed in 3 ongoing clinical trials in relapsed/refractory large B-cell non-Hodgkin lymphoma.

February 21st 2020, 7:12pm

Transplantation and Cellular Therapy Meetings

Shaji K. Kumar, MD, discusses the role of stem cell mobilization in multiple myeloma. This is important in patients with myeloma who are eligible for stem cell transplantation.